Meeting
2022 ASCO Annual Meeting
Efficacy proof-of-concept from a phase 1 study of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ in patients with refractory solid tumors.
Authors
T.R. Jeffry Evans
University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
T.R. Jeffry Evans , Nehal J. Lakhani , Hendrik-Tobias Arkenau , Meredith McKean , Stefan N. Symeonides , Fabio Massaiti Iwamoto , Jim Rotolo , Gina Capiaux , Rob Michel , Stephen Kaesshaefer , Alice Susannah Bexon , Gerald Steven Falchook
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
New Targets and New Technologies (non-IO)
Clinical Trial Registration Number
NCT04478279
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3014)
DOI
10.1200/JCO.2022.40.16_suppl.3014
Abstract #
3014
Poster Bd #
6
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Phase I trial and pharmacokinetic study of Tanibirumab, a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 in patients with refractory solid tumors.
First Author: Su Jin Lee
Poster
2024 ASCO Annual Meeting
A phase 1, multi-center, safety, feasibility, and preliminary efficacy study evaluating a single dose of UNO101 in relapsed or refractory, unresectable, primary, or metastatic cutaneous and subcutaneous malignancies.
First Author: Frederick M. Dirbas
Poster
2023 ASCO Annual Meeting
Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of GEC255, a novel KRASG12C inhibitor, in advanced solid tumors.
First Author: Yan Zhang
Poster
2023 ASCO Annual Meeting
A phase 1 dose-escalation study to investigate the safety, efficacy, pharmacokinetics, and pharmacodynamic activity of cln-619 (Anti-MICA/B antibody) alone and in combination with pembrolizumab in patients with advanced solid tumors.
First Author: Judy S. Wang